Related references
Note: Only part of the references are listed.HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA
Kazuma Sekiba et al.
JOURNAL OF HEPATOLOGY (2022)
Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma
Huat Chye Lim et al.
PLOS COMPUTATIONAL BIOLOGY (2021)
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
Ke Cong et al.
MOLECULAR CELL (2021)
PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?
Laetitia Gerossier et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2021)
Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex
Marissa M. Minor et al.
CELLS (2020)
DNA Double Strand Break Repair - Related Synthetic Lethality
Monika Toma et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing
Kornel Labun et al.
NUCLEIC ACIDS RESEARCH (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Defining and Modulating 'BRCAness'
Andrea K. Byrum et al.
TRENDS IN CELL BIOLOGY (2019)
Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus
Kazuma Sekiba et al.
HEPATOLOGY (2019)
Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction
Kazuma Sekiba et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2019)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Hepatitis B virus infection
Man-Fung Yuen et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
G. E. Konecny et al.
BRITISH JOURNAL OF CANCER (2016)
Destabilized SMC5/6 complex leads to chromosome breakage syndrome with severe lung disease
Saskia N. van der Crabben et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor
Adrien Decorsiere et al.
NATURE (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication
Christopher M. Murphy et al.
CELL REPORTS (2016)
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
Andrew Gabrielson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
Christine S. Walsh
GYNECOLOGIC ONCOLOGY (2015)
Improved vectors and genome-wide libraries for CRISPR screening
Neville E. Sanjana et al.
NATURE METHODS (2014)
Smc5/6: a link between DNA repair and unidirectional replication?
Johanne M. Murray et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Smc5-Smc6 mediate DNA double-strand-break repair by promoting sister-chromatid recombination
Giacomo De Piccoli et al.
NATURE CELL BIOLOGY (2006)
Human SMC5/6 complex promotes sister chromatid homologous recombination by recruiting the SMC1/3 cohesin complex to double-strand breaks
Patrick Ryan Potts et al.
EMBO JOURNAL (2006)
Share Paper
